Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial

Next Previous
X
Search
Trial Profile

Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levamisole (Primary)
  • Indications Nephrotic syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Ace Pharmaceuticals

    • Most Recent Events

    • 19 Dec 2013 According to an Ace Pharmaceuticals media release, Professor Jean Claude Davin and pediatrician Mariken Gruppen of the AMC (Academic Medical Center, Amsterdam) were acting as principal investigator (JCD) and study coordinator.
    • 19 Dec 2013 According to an Ace Pharmaceuticals media release, database lock date of this study was 19th December 2013.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top